You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for Patent: 7,572,779


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,572,779 protect, and when does it expire?

Patent 7,572,779 protects FEMTRACE and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 7,572,779
Title:Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Abstract:A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17.beta.-estradiol-3-lower alkanoate, most preferably 17.beta.-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed is a method for treating a human female in need of 17.beta.-estradiol and a contraceptive method by oral administration of the pharmaceutical dosage unit and a method of preparing a pharmaceutical composition that may be used to form the pharmaceutical dosage unit of the invention.
Inventor(s): Aloba; Oluwole T. (Morristown, NJ), deVries; Tina M (Long Valley, NJ)
Assignee: Warner Chilcott Company LLC (Fajardo, PR)
Application Number:10/833,997
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 7,572,779

Introduction

Patents are a crucial component of intellectual property law, providing inventors and innovators with exclusive rights to their inventions. The United States Patent 7,572,779, hereafter referred to as the '779 patent, is a specific example that can be analyzed to understand the broader patent landscape and the intricacies of patent claims and scope.

Background on Patent 7,572,779

To begin, it is essential to identify the subject matter of the '779 patent. However, since the specific details of this patent are not provided in the sources, we will use general principles and examples to illustrate how one would analyze such a patent.

Patent Claims

Independent and Dependent Claims

Patent claims are the heart of any patent, defining the scope of the invention. Independent claims stand alone and define the invention without reference to other claims, while dependent claims refer back to and further limit an independent claim[3].

Claim Length and Count

Research has shown that the length and count of independent claims can be metrics for measuring patent scope. Generally, narrower claims with shorter lengths and fewer counts are associated with a higher probability of grant and a shorter examination process[3].

Patent Scope

Metrics for Measuring Scope

Patent scope is often debated in terms of patent quality. Metrics such as independent claim length and count can provide insights into the breadth of the patent. Broader claims can lead to increased licensing and litigation costs, potentially diminishing innovation incentives[3].

Examination Process

The patent examination process tends to narrow the scope of patent claims. This is evident from studies showing that the duration of examination can significantly impact the final scope of the claims, with longer examinations often resulting in narrower claims[3].

Patent Landscape

Interrelated Patents

The '779 patent, like many others, may be part of a larger family of patents. For instance, the Cellect case illustrates how multiple patents can be interrelated, claiming priority from a single application or continuation-in-part of earlier patents. This can affect the patent term and the analysis of obviousness-type double patenting (ODP)[1].

Patent Term Adjustments (PTA)

Patent Term Adjustments can extend the life of a patent due to delays in the USPTO's prosecution process. However, these adjustments do not extend the term past the date of a terminal disclaimer, which is often used to overcome ODP rejections[1].

Practical Applications and Eligibility

Real-World Applications

For a patent to be eligible, it must demonstrate practical applications that solve specific problems or improve technology. This is particularly relevant in the context of AI and software patents, where abstract ideas must be integrated into concrete, practical applications to meet patent eligibility criteria[4].

Legal and Policy Considerations

Small Claims Patent Courts

The concept of small claims patent courts has been explored to address the high costs and complexities associated with patent litigation. Studies by the Administrative Conference of the United States (ACUS) have considered the feasibility and structure of such courts, highlighting the need for accessible and efficient dispute resolution mechanisms for smaller inventors and businesses[2].

Case Law and Precedents

Obviousness-Type Double Patenting (ODP)

The Cellect case provides insight into how ODP is analyzed, particularly in the context of patents with PTA. The Federal Circuit has held that a patent term extension under certain conditions does not foreclose the application of a terminal disclaimer, which can impact the analysis of ODP[1].

Industry Expert Insights

Industry experts and legal practitioners often weigh in on patent issues. For example, the ACUS study on small claims patent courts involved a consultative group of experts who advised on the methodology and implications of such a court. Their insights are crucial in shaping policy and legal frameworks around patent litigation[2].

Statistics and Trends

Patent Examination Outcomes

Studies have shown that the examination process can significantly impact the final scope of patent claims. For instance, narrower claims at publication are associated with a higher grant rate and shorter examination times. This trend highlights the importance of careful claim drafting and the potential benefits of narrower, more focused claims[3].

Key Takeaways

  • Patent Claims: Independent and dependent claims define the scope of the invention, with narrower claims often leading to a higher probability of grant and shorter examination times.
  • Patent Scope: Metrics like claim length and count can measure patent scope, with broader claims potentially increasing licensing and litigation costs.
  • Patent Term Adjustments: PTA can extend patent life but does not extend past the date of a terminal disclaimer.
  • Practical Applications: Patents must demonstrate real-world applications to be eligible, especially in fields like AI and software.
  • Legal and Policy Considerations: Small claims patent courts are being considered to address the high costs of patent litigation.

FAQs

Q: What is the significance of independent and dependent claims in a patent? A: Independent claims define the invention without reference to other claims, while dependent claims further limit an independent claim, providing additional specificity.

Q: How does the patent examination process affect the scope of patent claims? A: The examination process tends to narrow the scope of patent claims, with longer examinations resulting in more significant narrowing.

Q: What is the role of Patent Term Adjustments (PTA) in extending patent life? A: PTA extends the life of a patent due to USPTO delays but does not extend past the date of a terminal disclaimer.

Q: Why are practical applications important for patent eligibility? A: Practical applications are crucial for demonstrating how an abstract idea is transformed into a specific, practical application that provides clear benefits.

Q: What is the purpose of considering small claims patent courts? A: Small claims patent courts aim to provide an accessible and efficient dispute resolution mechanism for smaller inventors and businesses, reducing the high costs associated with patent litigation.

Sources

  1. In re Cellect, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. U.S. Patent Small Claims Court, Administrative Conference of the United States.
  3. Patent Claims and Patent Scope, SSRN, September 29, 2016.
  4. Understanding the 2024 USPTO Guidance Update on AI Patent, Mintz, July 25, 2024.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,572,779

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-001 Aug 20, 2004 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ⤷  Subscribe
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-002 Aug 20, 2004 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ⤷  Subscribe
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-003 Aug 20, 2004 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,572,779

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002359758 ⤷  Subscribe
Canada 2470703 ⤷  Subscribe
China 1273141 ⤷  Subscribe
China 1564689 ⤷  Subscribe
European Patent Office 1461043 ⤷  Subscribe
Israel 160797 ⤷  Subscribe
Japan 2005517673 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.